News Center

位置：

Honors Announcement

Group News

Media Reports

Shijiazhuang Sihua Pharmaceutical Group’s Innovative Development “Ignites” the 91st National Pharmaceutical Fair

Category:

Group News

发布时间：2025-11-20

【概要描述】 Nanjing in early winter boasts a distinctive charm. On November 19, the highly anticipated 91st National Pharmaceutical Fair (PHARMCHINA) kicked off with great fanfare here. The Group, along with more than 2,000 leading pharmaceutical and greater-health enterprises from across the country, gathered as scheduled to take part in this premier industry event.

Shijiazhuang Sihua Pharmaceutical Group’s Innovative Development “Ignites” the 91st National Pharmaceutical Fair

Nanjing in early winter boasts a unique charm. On November 19, the highly anticipated 91st National Pharmaceutical Fair (PHARMCHINA) kicked off with great fanfare here. The Group, along with more than 2,000 leading pharmaceutical and greater-health enterprises from across the country, gathered as scheduled to take part in this premier industry event.

The National Pharmaceutical Fair (PHARMCHINA) is a large-scale, highly influential professional event in China’s pharmaceutical preparations and greater health sectors. Over more than four decades of continuous innovation and development, it has evolved into a comprehensive and efficient platform for customer relationship building, new-product launches, business cooperation, trend analysis, information exchange, brand promotion, and business networking.

Upon entering the exhibition hall, the group’s booth was bustling with visitors. A wide array of newly launched products—including rosuvastatin–ezetimibe tablets (I), sitagliptin dry-mix suspension, urapidil sustained-release capsules, deferasirox dispersible tablets, progesterone injection (II), peritoneal dialysis solution, and large-package infusion bags—were showcased in a concentrated display, drawing extensive attention. An established customer remarked during a conversation with the group’s sales representatives: “In this 11th round of national centralized procurement, Shisi Pharmaceutical had so many products selected—truly impressive strength!” Many other visitors who had come specifically to learn more also stopped by to gain a detailed understanding of the company’s product features and advantages, creating a highly enthusiastic atmosphere on site. “I noticed that Shisi Pharmaceutical’s lincomycin hydrochloride injection was recently approved—let’s see if we can explore a collaboration,” one visitor said. Another added, “I’d like to learn more about the products involved in Shisi Pharmaceutical’s participation in the follow-up rounds of the first eight batches of national centralized procurement…” On the opening day, the group’s booth was packed with attendees, as its diverse portfolio of new and centrally procured products energized the entire event.

In recent years, the Group has remained firmly committed to the paramount task of high-quality development, taking it as its mission to research, develop, and manufacture more “Made-in-China” pharmaceuticals. With a keen focus on market demand and the cutting edge of industry development, the Group has strategically positioned itself in key therapeutic areas—including anti-infectives, respiratory diseases, neurological disorders, renal diseases, cardiovascular and cerebrovascular conditions, gastroenterology, anesthesia, endocrinology and dialysis, and oncology—while actively building a high-performance ecosystem for sustainable growth. Product innovation is being seamlessly integrated into a cohesive value chain, with synergies and scale driving cluster formation. Since the beginning of this year, the Group has secured approval for 80 new products and has achieved cumulative consistency evaluation for 157 drug varieties across 208 specifications. In the recently concluded 11th round of national centralized drug procurement, 12 varieties comprising 14 specifications were successfully selected, delivering outstanding results; in the recently launched follow-up procurement by the Guangdong Provincial Drug Alliance, 135 product specifications were successfully renewed. Moreover, in the upcoming list of follow-up products for the 1st through 8th rounds of nationally organized centralized drug procurement, the Group has 46 varieties included. This series of innovative breakthroughs and successful market access has built robust momentum for the Company to consolidate its existing market share while opening up new growth opportunities.

“We must translate the confidence and enthusiasm generated by this grand event into a powerful driving force for sprinting toward our year-end targets and charting the blueprint for 2026. Looking ahead to the 15th Five-Year Plan period, the company will take innovation as its engine and customers as its center, continuously leveraging the dual-engine synergy of API and finished dosage forms, deepening our strategic positioning in key areas, accelerating the launch of more high-value new products, and working hand-in-hand with our broad network of partners to co-create the future and better support the building of a Healthy China,” said the group’s leader.

Keywords:

The “Shimen” brand adds another golden accolade! Shijiazhuang Sihua Pharmaceutical has been recognized as one of the first “Time-Honored Brands of Shijiazhuang.”

Shijiazhuang Sihua Pharmaceutical Wins Multiple Prestigious Awards, Including a Place Among the Top 100 Manufacturing Enterprises in the Beijing-Tianjin-Hebei Region for 2025

The “Shimen” brand adds another golden accolade! Shijiazhuang Sihua Pharmaceutical has been recognized as one of the first “Time-Honored Brands of Shijiazhuang.”

Shijiazhuang Sihua Pharmaceutical Wins Multiple Prestigious Awards, Including a Place Among the Top 100 Manufacturing Enterprises in the Beijing-Tianjin-Hebei Region for 2025